Galectin Therapeutics Inc.
GALT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $12 | $14 | $7 | $15 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1 | $2 | $2 | $2 |
| Total Curr. Assets | $13 | $15 | $9 | $17 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $13 | $16 | $10 | $17 |
| Liabilities | – | – | – | – |
| Payables | $5 | $6 | $7 | $6 |
| Short-Term Debt | $122 | $0 | $97 | $21 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $9 | $5 | $7 | $9 |
| Total Curr. Liab. | $136 | $11 | $111 | $35 |
| LT Debt | $0 | $120 | $11 | $85 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $2 | $2 | $0 | $0 |
| Total NC Liab. | $2 | $122 | $11 | $85 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $138 | $133 | $122 | $121 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $2 | $2 | $2 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$427 | -$419 | -$411 | -$402 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $301 | $299 | $297 | $296 |
| Total Equity | -$125 | -$117 | -$112 | -$103 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $13 | $16 | $10 | $17 |
| Net Debt | $111 | $107 | $101 | $91 |